Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Novartis AG — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 74.2× iShares MSCI United Kingdom (FTSE)'s market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Novartis AG for 82 Days on average.
| EWU | NVS | |
|---|---|---|
Market Cap | $3.62B | $268.57B |
Volume | 923,896 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $168.62 |
52-Week Low | $41.34 | $121.80 |
Typical Hold Time | 46 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU is trading at $46.52, up 1.28% today, but faces significant technical headwinds with a bearish overall signal. The stock shows mixed technical indicators with oversold RSI levels but strong bearish momentum signals from ADX. Recent UK market volatility, driven by rising gilt yields and inflation concerns, creates a challenging environment for this UK-focused ETF.
The outlook remains cautious as UK economic pressures mount, with rising borrowing costs and energy price inflation creating headwinds. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include continued UK market volatility and persistent inflation pressures that could pressure UK equities.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
